Home ›
Diffuse Large B-Cell (DLBCL) Lymphoma Trials ›
NCT06682130
Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCL
The objective of this study is to evaluate the efficacy and safety of the Glofitamab bridging ASCT regimen in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and to provide better clinical benefits to these patients.
Trial Details
NCT ID NCT06682130
Phase PHASE2
Sponsor The First Affiliated Hospital of Soochow University
Status RECRUITING
Cancer Type Diffuse Large B-Cell (DLBCL) Lymphoma
Interventions Group A:Patients with PR or ctDNA positivity after salvage treatment Group B: Patients with CR and ctDNA negative after salvage treatment Group C: Patients with SD/PD after posterior treatment
Locations (sample) Suzhou, Jiangsu, China|31.30408,120.59538
Key Eligibility Criteria
Patients with diffuse large B-cell lymphoma (DLBCL) confirmed by histopathology/cytology using the 2022 World Health Organization (WHO) Classificat… Patients with R/R DLBCL who have received at least two lines of systemic treatment; Age range: 18-70 years old, male or female not limited; When the disease recurs or is difficult to treat, there are assessable lesions (lymph node diameter ≥ 1.0cm; or skin lesions assessable by physical…
For full eligibility, visit ClinicalTrials.gov .